Skip to content

Assessment of potential effects of elinogrel on steady-state pharmacokinetics of atorvastatin in healthy adult subjects

An open-label, randomized, 2-way, cross-over study, to assess the potential effect of elinogrel on the steady-state pharmacokinetics of atorvastatin in healthy adult subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610000640000
Enrollment
22
Registered
2010-08-06
Start date
2010-08-11
Completion date
2010-10-11
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Elinogrel is under development for the treatment of patients with chronic coronary heart disease and acute coronary syndromes. Patients treated for these conditions are likley to be on a statin therapy such as atorvastatin in addition to other anticoagulants such as elinogrel. Hence the need to investigate the potential drug-drug interaction between elinogrel and atorvastatin.

Interventions

Atorvastatin 40 mg (oral tablet) once daily (QD) plus Elinogrel 150mg (oral capsule) twice daily (BD) for 5 days (treatment 2) Each participant will take both treatments 1 and 2. One at a time, seperated by a 5 day washout period. The treatment taken first will depend on randomistion (similar to the flip of a coin)

Sponsors

Nucleus Network
Lead SponsorOther

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

- adult subjects aged 18 to 45 - Body Mass Index (BMI) between 18 and 32 Kg/m2 - Change between seated and standing blood pressure less than 20 mmHg for systolic blood pressure and 10 mmHg for diastolic blood pressure.

Exclusion criteria

- Women of childbearing potential unless using suitable contraception methods - Bleeding time tests out of normal laboratory range - Abnormal liver function test results - Other protocol-defined inclusion/exclusion criteria may apply

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026